Delta-Fly Pharma Competitors and Similar CompaniesClear all

Delta-Fly Pharma's competitors and similar companies include Cadent Therapeutics, Tonix Pharmaceuticals, Sara Pharm Solutions and Wuhan Orient Honest Medical.

	Delta-Fly Pharma Delta-Fly Pharma 株式会社（デルタフライファーマ is a manufacturer and seller of anti-cancer agents and other products.	Cadent Therapeutics Cadent Therapeutics is a neuroscience company that develops a pipeline of medicines.	Tonix Pharmaceuticals Tonix Pharmaceuticals develops pharmaceutical products for central nervous system disorders.	Sara Pharm Solutions Sara Pharm Solutions is a company that focuses on advanced materials and catalysis.	Wuhan Orient Honest Medical Wuhan Orient Honest Medical is a company that develops and manufactures pharmaceutical products.
Founding Date	Founding Date 2010	Founding Date 2017	Founding Date 2007	Founding Date 2011	Founding Date 2001
Type	Type Public	Type Private	Type Public	Type Private	Type Private
Tags	Tags Healthcare drug development medtech	Tags Healthcare drug development medtech	Tags Healthcare drug development medtech pharma	Tags Healthcare advanced materials drug development medtech	Tags Healthcare drug development medtech pharma
Locations	Locations HQ	Locations Cambridge, US HQ	Locations Chatham, US HQ Montréal, CA Dublin, IE Dartmouth, US New York, US San Diego, US	Locations București, RO HQ	Locations 武汉市, CN HQ
Employees	Employees N/A	Employees 264% increase	Employees 1633% increase	Employees 6	Employees N/A
Valuation ($)	Valuation ($) 29.5 m	Valuation ($) N/A	Valuation ($) 23.5 m	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) $13.1m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods (¥1.6m) (FY, 2025)	Cost of goods N/A	Cost of goods $6.6m (FY, 2025)	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit ¥1.6m (FY, 2025)	Gross profit N/A	Gross profit $6.5m (FY, 2025)	Gross profit N/A	Gross profit N/A
Net income	Net income (¥1.7b) (FY, 2025)	Net income N/A	Net income ($124m) (FY, 2025)	Net income N/A	Net income N/A
Funding
Total funding raised	Total funding raised N/A	Total funding raised $ 51.7m	Total funding raised $ 15.5m	Total funding raised N/A	Total funding raised N/A